primary goat polyclonal antibody against shox2 sc-21898  (Santa Cruz Biotechnology)

Journal: Oxidative Medicine and Cellular Longevity

Article Title: NRF-2/HO-1 Pathway-Mediated SHOX2 Activation Is a Key Switch for Heart Rate Acceleration by Yixin-Fumai Granules

doi: 10.1155/2022/8488269

Figure Lengend Snippet: siRNA target sequences.

Article Snippet: We purchased VSNL1 polyclonal antibody and AlexaFluor488-conjugated AffiniPure goat anti-chicken IgY from Abcam (USA); SHOX2 Polyclonal Antibody from Bioss (China); NRF-2 polyclonal antibody, CACNA1G polyclonal antibody, and CoraLite488- and CoraLite594-conjugated AffiniPure Goat anti-rabbit IgG from Proteintech (China); and 4% paraformaldehyde, Triton X-100, and antifade mounting medium with DAPI from Beyotime Biotechnology (China).

Techniques: Sequencing

Journal: Oxidative Medicine and Cellular Longevity

Article Title: NRF-2/HO-1 Pathway-Mediated SHOX2 Activation Is a Key Switch for Heart Rate Acceleration by Yixin-Fumai Granules

doi: 10.1155/2022/8488269

Figure Lengend Snippet: RT-qPCR primers.

Article Snippet: We purchased VSNL1 polyclonal antibody and AlexaFluor488-conjugated AffiniPure goat anti-chicken IgY from Abcam (USA); SHOX2 Polyclonal Antibody from Bioss (China); NRF-2 polyclonal antibody, CACNA1G polyclonal antibody, and CoraLite488- and CoraLite594-conjugated AffiniPure Goat anti-rabbit IgG from Proteintech (China); and 4% paraformaldehyde, Triton X-100, and antifade mounting medium with DAPI from Beyotime Biotechnology (China).

Techniques:

Journal: Oxidative Medicine and Cellular Longevity

Article Title: NRF-2/HO-1 Pathway-Mediated SHOX2 Activation Is a Key Switch for Heart Rate Acceleration by Yixin-Fumai Granules

doi: 10.1155/2022/8488269

Figure Lengend Snippet: YXFMs thwart CACNA1G reduction within SSS mice SAN. (a) Immunofluorescence staining assay for VSNL1 and CACNA1G (scale = 20 μ m). (b) Western blotting assay for SHOX2. (c, d) Comparative analyses for Western blotting results and fluorescence intensities. ∗∗ P < 0.01 in comparison to the CON group, ## P < 0.01 and # P < 0.05 in comparison to the SSS group. CON: control group; SSS: sick sinus syndrome group; YXFMs: Yixin-Fumai granule-administered group.

Article Snippet: We purchased VSNL1 polyclonal antibody and AlexaFluor488-conjugated AffiniPure goat anti-chicken IgY from Abcam (USA); SHOX2 Polyclonal Antibody from Bioss (China); NRF-2 polyclonal antibody, CACNA1G polyclonal antibody, and CoraLite488- and CoraLite594-conjugated AffiniPure Goat anti-rabbit IgG from Proteintech (China); and 4% paraformaldehyde, Triton X-100, and antifade mounting medium with DAPI from Beyotime Biotechnology (China).

Techniques: Immunofluorescence, Staining, Western Blot, Fluorescence

Journal: Oxidative Medicine and Cellular Longevity

Article Title: NRF-2/HO-1 Pathway-Mediated SHOX2 Activation Is a Key Switch for Heart Rate Acceleration by Yixin-Fumai Granules

doi: 10.1155/2022/8488269

Figure Lengend Snippet: YXFMs activated NRF-2 and improve SHOX2 deficiency in senescent HL-1 cells. (a) DCFH-DA staining for ROS assay (scale = 50 μ m). (b) Immunofluorescence staining for NRF-2 and SHOX2 assay (scale = 10 μ m). (c) Comparative analyses for ROS content. (d) Comparative analyses for the NRF-2 and SHOX2 expression. ∗∗ P < 0.01 and ∗ P < 0.05 in comparison to the CON group, ## P < 0.01 in comparison to the senescence group, △△ P < 0.01 in comparison to the YXFM group. CON: control group; senescence: D-galactose administered group; YXFMs: D-galactose + Yixin-Fumai granule-administered group; YXFMs + ML385: D-galactose + Yixin-Fumai granule + NRF-2 inhibitor ML385-administered group; H 2 O 2 : hydrogen peroxide-administered group.

Article Snippet: We purchased VSNL1 polyclonal antibody and AlexaFluor488-conjugated AffiniPure goat anti-chicken IgY from Abcam (USA); SHOX2 Polyclonal Antibody from Bioss (China); NRF-2 polyclonal antibody, CACNA1G polyclonal antibody, and CoraLite488- and CoraLite594-conjugated AffiniPure Goat anti-rabbit IgG from Proteintech (China); and 4% paraformaldehyde, Triton X-100, and antifade mounting medium with DAPI from Beyotime Biotechnology (China).

Techniques: Staining, ROS Assay, Immunofluorescence, Expressing

Journal: Oxidative Medicine and Cellular Longevity

Article Title: NRF-2/HO-1 Pathway-Mediated SHOX2 Activation Is a Key Switch for Heart Rate Acceleration by Yixin-Fumai Granules

doi: 10.1155/2022/8488269

Figure Lengend Snippet: YXFMs improve pulsatile dysfunction in senescent hiPSC-AMs. (a) Field potential traces of hiPSC-AMs. (b, c) Comparative analyses for the beat rate and field potential duration of hiPSC-AMs. ∗∗ P < 0.01 in comparison to the CON group, ## P < 0.01 and # P < 0.05 in comparison to the senescence group, △△ P < 0.01 in comparison to the YXFM group; NS: no statistical significance; CON: control group; senescence: D-galactose administered group; YXFMs: D-galactose + Yixin-Fumai granule-administered group; YXFMs + si-NC: D-galactose + Yixin-Fumai granule-administered + si- NC transfection group; YXFMs + si- SHOX2 : D-galactose + Yixin-Fumai granule-administered + si- SHOX2 transfection group; YXFMs + ML385: D-galactose + Yixin-Fumai granules + NRF2 inhibitor ML385-administered group.

Article Snippet: We purchased VSNL1 polyclonal antibody and AlexaFluor488-conjugated AffiniPure goat anti-chicken IgY from Abcam (USA); SHOX2 Polyclonal Antibody from Bioss (China); NRF-2 polyclonal antibody, CACNA1G polyclonal antibody, and CoraLite488- and CoraLite594-conjugated AffiniPure Goat anti-rabbit IgG from Proteintech (China); and 4% paraformaldehyde, Triton X-100, and antifade mounting medium with DAPI from Beyotime Biotechnology (China).

Techniques: Transfection

Journal: Oxidative Medicine and Cellular Longevity

Article Title: NRF-2/HO-1 Pathway-Mediated SHOX2 Activation Is a Key Switch for Heart Rate Acceleration by Yixin-Fumai Granules

doi: 10.1155/2022/8488269

Figure Lengend Snippet: YXFMs improve pulsatile function in SHOX2-silenced hiPSC-AMs. (a) Field potential traces of hiPSC-AMs. (b, c) Statistical results for the beat rate and field potential duration of hiPSC-AMs. ∗∗ P < 0.01 in comparison to the si-NC group, ## P < 0.01 and # P < 0.05 in comparison to the si- SHOX2 group, △△ P < 0.01 in comparison to the YXFM group; NS: no statistical significance; CON: control group; si-NC: si-NC transfection group; si- SHOX2 : si- SHOX2 transfection group; YXFMs: si- SHOX2 transfection + Yixin-Fumai granule-administered group; SB4: si- SHOX2 transfection + BMP4 activator SB4-administered group; YXFMs + LDN193189: si- SHOX2 transfection + Yixin-Fumai granule + BMP4 inhibitor LDN193189-administered group. YXFMs + mibefradil: si- SHOX2 transfection + Yixin-Fumai granule + T-type calcium channel inhibitor mibefradil-administered group.

Article Snippet: We purchased VSNL1 polyclonal antibody and AlexaFluor488-conjugated AffiniPure goat anti-chicken IgY from Abcam (USA); SHOX2 Polyclonal Antibody from Bioss (China); NRF-2 polyclonal antibody, CACNA1G polyclonal antibody, and CoraLite488- and CoraLite594-conjugated AffiniPure Goat anti-rabbit IgG from Proteintech (China); and 4% paraformaldehyde, Triton X-100, and antifade mounting medium with DAPI from Beyotime Biotechnology (China).

Techniques: Transfection

Journal: Oxidative Medicine and Cellular Longevity

Article Title: NRF-2/HO-1 Pathway-Mediated SHOX2 Activation Is a Key Switch for Heart Rate Acceleration by Yixin-Fumai Granules

doi: 10.1155/2022/8488269

Figure Lengend Snippet: YXFMs increase CACNA1G expression through SHOX2 upregulation. (a) CACNA1G expression in HL-1 cells (scale = 10 μ m). (b) Comparative analyses for RT-qPCR. (c) Comparative analyses for immunofluorescence staining. (d) Western blotting assay for SHOX2, BMP4, GATA4, and NKX2-5 in HL-1 cells. (e) Comparative analyses for Western blotting. ∗∗ P < 0.01 and ∗ P < 0.05 in comparison to the si-NC group, ## P < 0.01 and # P < 0.05 in comparison to the si- Shox2 group. NS: no statistical significance; CON: control group; si-NC: si-NC transfection group; si- Shox2 : si- Shox2 transfection group; YXFMs: si- Shox2 transfection + Yixin-Fumai granule-administered group; SB4: si- Shox2 transfection + BMP4 activator SB4-administered group.

Article Snippet: We purchased VSNL1 polyclonal antibody and AlexaFluor488-conjugated AffiniPure goat anti-chicken IgY from Abcam (USA); SHOX2 Polyclonal Antibody from Bioss (China); NRF-2 polyclonal antibody, CACNA1G polyclonal antibody, and CoraLite488- and CoraLite594-conjugated AffiniPure Goat anti-rabbit IgG from Proteintech (China); and 4% paraformaldehyde, Triton X-100, and antifade mounting medium with DAPI from Beyotime Biotechnology (China).

Techniques: Expressing, Quantitative RT-PCR, Immunofluorescence, Staining, Western Blot, Transfection

Journal: Oxidative Medicine and Cellular Longevity

Article Title: NRF-2/HO-1 Pathway-Mediated SHOX2 Activation Is a Key Switch for Heart Rate Acceleration by Yixin-Fumai Granules

doi: 10.1155/2022/8488269

Figure Lengend Snippet: The mechanism of YXFMs improving SAN dysfunction: NRF-2/HO-1 pathway-mediated SHOX2 activation is a key switch.

Article Snippet: We purchased VSNL1 polyclonal antibody and AlexaFluor488-conjugated AffiniPure goat anti-chicken IgY from Abcam (USA); SHOX2 Polyclonal Antibody from Bioss (China); NRF-2 polyclonal antibody, CACNA1G polyclonal antibody, and CoraLite488- and CoraLite594-conjugated AffiniPure Goat anti-rabbit IgG from Proteintech (China); and 4% paraformaldehyde, Triton X-100, and antifade mounting medium with DAPI from Beyotime Biotechnology (China).

Techniques: Activation Assay

Journal: Molecular Medicine Reports

Article Title: Shox2 influences mesenchymal stem cell fate in a co-culture model in vitro

doi: 10.3892/mmr.2016.5306

Figure Lengend Snippet: Primers used in reverse transcription-quantitative polymerase chain reaction analyses.

Article Snippet: The membranes were then incubated with primary goat polyclonal antibody against Shox2 (cat. no. sc-21898, Santa Cruz Biotechnology Inc.; 1:200) and GAPDH (cat. no. sc-48166, Santa Cruz Biotechnology Inc.; 1:200) and rabbit polyclonal antibodies against Tbx3 (cat. no. sc-48781, Santa Cruz Biotechnology Inc.; 1:200), Cx45 (cat. no. sc-25716, Santa Cruz Biotechnology Inc.; 1:200), Cx43 (cat. no. sc-9059, Santa Cruz Biotechnology Inc.; 1:200), HCN4 (cat. no. ab69054, Abcam, Cambridge, UK; 1:100) and Nkx2.5 (cat. no. ab97355, Abcam, UK; 1:500) were incubated separately overnight at 4°C with gentle agitation.

Techniques: Polymerase Chain Reaction

Journal: Molecular Medicine Reports

Article Title: Shox2 influences mesenchymal stem cell fate in a co-culture model in vitro

doi: 10.3892/mmr.2016.5306

Figure Lengend Snippet: Characterization of cMSCs. (A) Laser confocal microscopy of cMSCs after transfection. cMSCs were transfected with pLentis-mShox2-RFP, as evidenced by the expression of Shox2. Nuclei were stained blue with 4′,6-diamidino-2-phenylindole as a control. (B) Fluorescence images of 1:4 cMSCs: RNCMs co-cultured on day 5 after plating. cMSCs were randomly distributed in culture. Scale bar, 50 µ m. (C) Shox2-transfected cMSCs expressing Cx45 were co-cultured with RNCMs. None of the control cells displayed this positive expression. Scale bar, 20 µ m. cMSC, canine mesenchymal stem cells; NRMCs, rat neonatal cardiomyocytes; Shox2, short stature homeobox 2; Cx45, Connexin 45; RFP, red fluorescent protein.

Article Snippet: The membranes were then incubated with primary goat polyclonal antibody against Shox2 (cat. no. sc-21898, Santa Cruz Biotechnology Inc.; 1:200) and GAPDH (cat. no. sc-48166, Santa Cruz Biotechnology Inc.; 1:200) and rabbit polyclonal antibodies against Tbx3 (cat. no. sc-48781, Santa Cruz Biotechnology Inc.; 1:200), Cx45 (cat. no. sc-25716, Santa Cruz Biotechnology Inc.; 1:200), Cx43 (cat. no. sc-9059, Santa Cruz Biotechnology Inc.; 1:200), HCN4 (cat. no. ab69054, Abcam, Cambridge, UK; 1:100) and Nkx2.5 (cat. no. ab97355, Abcam, UK; 1:500) were incubated separately overnight at 4°C with gentle agitation.

Techniques: Confocal Microscopy, Transfection, Expressing, Staining, Control, Fluorescence, Cell Culture

Journal: Molecular Medicine Reports

Article Title: Shox2 influences mesenchymal stem cell fate in a co-culture model in vitro

doi: 10.3892/mmr.2016.5306

Figure Lengend Snippet: Shox2, Tbx3, HCN4, Cx45, Nkx2.5 and Cx43 gene expression was examined using reverse transcription-quantitative polymerase chain reaction. Similar results were obtained in three independent experiments. Data are presented as the mean ± standard error of the mean. * P<0.05 vs. control. Shox2, Short stature homeobox 2; Tbx3, T box 3; HCN4, hyperpolarization-activated cyclic nucleotide-gated cation channel; Cx45, connexin 45; Cx43, Connexin 43; RFP, red fluorescent protein; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; RNCMs, rat neonatal cardiomyocytes.

Article Snippet: The membranes were then incubated with primary goat polyclonal antibody against Shox2 (cat. no. sc-21898, Santa Cruz Biotechnology Inc.; 1:200) and GAPDH (cat. no. sc-48166, Santa Cruz Biotechnology Inc.; 1:200) and rabbit polyclonal antibodies against Tbx3 (cat. no. sc-48781, Santa Cruz Biotechnology Inc.; 1:200), Cx45 (cat. no. sc-25716, Santa Cruz Biotechnology Inc.; 1:200), Cx43 (cat. no. sc-9059, Santa Cruz Biotechnology Inc.; 1:200), HCN4 (cat. no. ab69054, Abcam, Cambridge, UK; 1:100) and Nkx2.5 (cat. no. ab97355, Abcam, UK; 1:500) were incubated separately overnight at 4°C with gentle agitation.

Techniques: Gene Expression, Reverse Transcription, Real-time Polymerase Chain Reaction, Control

Journal: Molecular Medicine Reports

Article Title: Shox2 influences mesenchymal stem cell fate in a co-culture model in vitro

doi: 10.3892/mmr.2016.5306

Figure Lengend Snippet: Shox2, Tbx3, HCN4, Cx45, Nkx2.5 and Cx43 protein expression were examined using western blotting. Similar results were obtained in three independent experiments. Shox2, Short stature homeobox 2; Tbx3, T box 3; HCN4, hyperpolarization-activated cyclic nucleotide-gated cation channel; Cx45, connexin 45; Cx43, Connexin 43; RFP, red fluorescent protein; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; RNCMs, rat neonatal cardiomyocytes.

Article Snippet: The membranes were then incubated with primary goat polyclonal antibody against Shox2 (cat. no. sc-21898, Santa Cruz Biotechnology Inc.; 1:200) and GAPDH (cat. no. sc-48166, Santa Cruz Biotechnology Inc.; 1:200) and rabbit polyclonal antibodies against Tbx3 (cat. no. sc-48781, Santa Cruz Biotechnology Inc.; 1:200), Cx45 (cat. no. sc-25716, Santa Cruz Biotechnology Inc.; 1:200), Cx43 (cat. no. sc-9059, Santa Cruz Biotechnology Inc.; 1:200), HCN4 (cat. no. ab69054, Abcam, Cambridge, UK; 1:100) and Nkx2.5 (cat. no. ab97355, Abcam, UK; 1:500) were incubated separately overnight at 4°C with gentle agitation.

Techniques: Expressing, Western Blot

Journal: Neoplasia (New York, N.Y.)

Article Title: SHOX2 is a direct miR-375 target and a novel epithelial-to-mesenchymal transition inducer in breast cancer cells.

doi: 10.1016/j.neo.2014.03.010

Figure Lengend Snippet: Figure 1. SHOX2 is a miR-375 target. (A) qRT-PCR analysis of SHOX2 expression in breast cancer cell lines. Data are means ± SEM (n = 3). (B) qRT-PCR analysis of miR-375 expression in breast cancer cell lines. Data are means ± SEM (n = 3). (C) Western blot analyses of SHOX2, E-cadherin, and vimentin expression in breast cancer cell lines. β-Actin was used as control. (D) Western blot analysis was used to analyze the effect of miR-375 on SHOX2 expression. miR-375 was lentivirally introduced into MDA-MB-231 and Hs578T cells, followed by the treatment with or without anti–miR-375. β-Actin was used as control. (E) Representation of miR-375 binding sites in the 3′-UTR of SHOX2 mRNA and the mutations generated in this region. Alphabetical numbers are the relative nucleotide positions in the 3′-UTR of SHOX2 mRNA. (F) pMiR containing SHOX2 3′-UTR with or without mutation in miR-375 targeting site was cotransfected into miR-375– transduced MDA-MB-231 and Hs578T cells for 2 days, followed by the analysis of luciferase activity. Data are means ± SEM (n = 3). #P b .01. *P b .05 versus control.

Article Snippet: They include SHOX2 polyclonal antibody (kindly provided by Dr Yi-Ping Chen at Tulane University, New Orleans, LA), Vimentin mAb (Santa Cruz Biotechnology, Santa Cruz, CA, CatalogNo. sc-6260), E-cadherin monolyclonal antibody (BD Biosciences, San Jose, CA, Catalog No. 610405), β-Actin mAb (Santa Cruz Biotechnology, Catalog DAPI E Control SHOX2 DAPI Control SHOX2 A B Figure W1.

Techniques: Quantitative RT-PCR, Expressing, Western Blot, Control, Binding Assay, Generated, Mutagenesis, Luciferase, Activity Assay

Journal: Neoplasia (New York, N.Y.)

Article Title: SHOX2 is a direct miR-375 target and a novel epithelial-to-mesenchymal transition inducer in breast cancer cells.

doi: 10.1016/j.neo.2014.03.010

Figure Lengend Snippet: Figure 2. miR-375 suppresses EMT by diminishing SHOX2 expression. (A) Western blot analysis was used to determine the effect of ectopic SHOX2 expression on E-cadherin and vimentin expression. β-Actin was used as control. (B) Matrigel invasion assay was used to analyze the effect of ectopic SHOX2 expression on in vitro invasion of miR-375–trasduced MDA-MB-231 and Hs578T cells. Data are means ± SEM (n = 3). #P b .05. *P b .05 versus miR-control. (C) qRT-PCR was used to determine the effect of SHOX2 knockdown on E-cadherin and vimentin expression. Data are means ± SEM (n = 3). *P b .05 versus shControl. (D) Western blot analysis was used to determine the effect of SHOX2 knockdown on E-cadherin and vimentin expression. β-Actin was used as control. (E) Morphologies of control and SHOX2 knockdown MDA-MB-231 and Hs578T cells. (F) Transwell migration assay was used to analyze the effect of SHOX2 knockdown on cell motility. Data are means ± SEM (n = 3). *P b .05 versus shControl.

Article Snippet: They include SHOX2 polyclonal antibody (kindly provided by Dr Yi-Ping Chen at Tulane University, New Orleans, LA), Vimentin mAb (Santa Cruz Biotechnology, Santa Cruz, CA, CatalogNo. sc-6260), E-cadherin monolyclonal antibody (BD Biosciences, San Jose, CA, Catalog No. 610405), β-Actin mAb (Santa Cruz Biotechnology, Catalog DAPI E Control SHOX2 DAPI Control SHOX2 A B Figure W1.

Techniques: Expressing, Western Blot, Control, Invasion Assay, In Vitro, Quantitative RT-PCR, Knockdown, Transwell Migration Assay

Journal: Neoplasia (New York, N.Y.)

Article Title: SHOX2 is a direct miR-375 target and a novel epithelial-to-mesenchymal transition inducer in breast cancer cells.

doi: 10.1016/j.neo.2014.03.010

Figure Lengend Snippet: Figure 3. SHOX2 induces EMT traits in epithelial-like breast cancer cells. (A) qRT-PCR was used to determine the effect of ectopic SHOX2 expression on E-cadherin and vimentin expression. Data are means ± SEM (n = 3). #P b .01 versus Control. *P b .05 versus Control. (B) Western blot analysis was used to determine the effect of ectopic SHOX2 expression on E-cadherin and vimentin expression. β-Actin was used as control. (C) Morphologies of control and SHOX2-transduced MCF7 and T47D cells. (D) Transwell migration assay was used to analyze the effect of ectopic SHOX2 expression on cell motility. Data are means ± SEM (n = 3). *P b .05 versus Control.

Article Snippet: They include SHOX2 polyclonal antibody (kindly provided by Dr Yi-Ping Chen at Tulane University, New Orleans, LA), Vimentin mAb (Santa Cruz Biotechnology, Santa Cruz, CA, CatalogNo. sc-6260), E-cadherin monolyclonal antibody (BD Biosciences, San Jose, CA, Catalog No. 610405), β-Actin mAb (Santa Cruz Biotechnology, Catalog DAPI E Control SHOX2 DAPI Control SHOX2 A B Figure W1.

Techniques: Quantitative RT-PCR, Expressing, Control, Western Blot, Transwell Migration Assay

Journal: Neoplasia (New York, N.Y.)

Article Title: SHOX2 is a direct miR-375 target and a novel epithelial-to-mesenchymal transition inducer in breast cancer cells.

doi: 10.1016/j.neo.2014.03.010

Figure Lengend Snippet: Figure 4. SHOX2 induces EMT through TGFβ signaling network. (A) Effect of LY364947 on morphologies of control and SHOX2- transduced MCF7 and T47D cells. (B) Western blot analysis was used to determine the effect of LY364947 on E-cadherin and vimentin expression in control and SHOX2-transduced MCF7 and T47D cells. β-Actin was used as control. (C) qRT-PCR was used to determine the effect of ectopic SHOX2 expression on TβR-I, TβR-II, and TβR-III expression in MCF7 and T47D cells. Data are means ± SEM (n = 3). *, P b .05 versus Control. (D) Western blot analysis was used to determine the effect of ectopic SHOX2 expression on TβR-I, TβR-II, and TβR-III expression in MCF7 and T47D cells. (E) qRT-PCR was used to determine the effect of SHOX2 knockdown on TβR-I, TβR-II, and TβR- III expression in MDA-MB-231 and Hs578T cells. Data are means ± SEM (n = 3). *P b .05 versus shControl. (F) Western blot analysis was used to determine the effect of SHOX2 knockdown on TβR-I, TβR-II, and TβR-III expression in MDA-MB-231 and Hs578T cells.

Article Snippet: They include SHOX2 polyclonal antibody (kindly provided by Dr Yi-Ping Chen at Tulane University, New Orleans, LA), Vimentin mAb (Santa Cruz Biotechnology, Santa Cruz, CA, CatalogNo. sc-6260), E-cadherin monolyclonal antibody (BD Biosciences, San Jose, CA, Catalog No. 610405), β-Actin mAb (Santa Cruz Biotechnology, Catalog DAPI E Control SHOX2 DAPI Control SHOX2 A B Figure W1.

Techniques: Control, Western Blot, Expressing, Quantitative RT-PCR, Knockdown

Journal: Neoplasia (New York, N.Y.)

Article Title: SHOX2 is a direct miR-375 target and a novel epithelial-to-mesenchymal transition inducer in breast cancer cells.

doi: 10.1016/j.neo.2014.03.010

Figure Lengend Snippet: Figure 5. SHOX2 transcriptionally regulates TβR-I expression. (A) Effect of SHOX2 knockdown on TβR-I promoter activity in MDA-MB-231 and Hs578T cells. Data are means ± SEM (n = 3). #P b .01 versus shControl. (B) Effect of ectopic SHOX2 expression on TβR-I promoter activity in MCF7 and T47D cells. Data are means ± SEM (n = 3). #P b .01 versus Control. (C) Effect of mutation in putative SHOX2-binding site on TβR-I promoter activity in MDA-MB-231 and Hs578T cells or SHOX2-induced TβR-I promoter activity in MCF7 and T47D cells. Data are means ± SEM (n = 3). #P b .01 versus wild-type (WT) or SHOX2 (−). (D) FLAG-SHOX2-transduced MDA-MB-231 cells were subjected to ChIP with FLAG mAb or mouse IgG. Quantitative PCR (qPCR) was performed using a primer set that amplifies various regions in TβR-I promoter. Data are means ± SEM (n = 3). *P b .05 versus Control (mouse IgG).

Article Snippet: They include SHOX2 polyclonal antibody (kindly provided by Dr Yi-Ping Chen at Tulane University, New Orleans, LA), Vimentin mAb (Santa Cruz Biotechnology, Santa Cruz, CA, CatalogNo. sc-6260), E-cadherin monolyclonal antibody (BD Biosciences, San Jose, CA, Catalog No. 610405), β-Actin mAb (Santa Cruz Biotechnology, Catalog DAPI E Control SHOX2 DAPI Control SHOX2 A B Figure W1.

Techniques: Expressing, Knockdown, Activity Assay, Control, Mutagenesis, Binding Assay, Real-time Polymerase Chain Reaction

Journal: Neoplasia (New York, N.Y.)

Article Title: SHOX2 is a direct miR-375 target and a novel epithelial-to-mesenchymal transition inducer in breast cancer cells.

doi: 10.1016/j.neo.2014.03.010

Figure Lengend Snippet: Figure 6. SHOX2 is functionally associated with breast tumorigenicity. (A) Univariate survival method (Kaplan-Meier method) of patients with breast cancer indicates a strong correlation between SHOX expression and recurrence-free survival (P = .041; log-rank test). (B) Univariate survival method (Kaplan-Meier method) of patients with breast cancer indicates a strong correlation between SHOX expression and overall survival (P = .041; log-rank test). (C) Multivariate survival analysis (proportional hazards method) shows a positive, independent prognostic importance of SHOX2 expression (P b .05; likelihood ratio test), in addition to the independent prognostic impact of lymph node status and PGR positivity. HR, hazard ratio. (D) Effect of ectopic SHOX2 expression on in vitro invasion of MCF7 and T47D cells. Data are means ± SEM (n = 3). *P b .05 versus Control. (E) Effect of SHOX2 knockdown on in vitro invasion of MDA-MB-231 and Hs578T cells. Data are means ± SEM (n = 3). *P b .05 versus shControl. (F) Effect of SHOX2 knockdown on in vivo dissemination of MDA- MB-231 in zebrafish. (G) Effect of ectopic SHOX2 expression on in vivo dissemination of T47D in zebrafish.

Article Snippet: They include SHOX2 polyclonal antibody (kindly provided by Dr Yi-Ping Chen at Tulane University, New Orleans, LA), Vimentin mAb (Santa Cruz Biotechnology, Santa Cruz, CA, CatalogNo. sc-6260), E-cadherin monolyclonal antibody (BD Biosciences, San Jose, CA, Catalog No. 610405), β-Actin mAb (Santa Cruz Biotechnology, Catalog DAPI E Control SHOX2 DAPI Control SHOX2 A B Figure W1.

Techniques: Expressing, In Vitro, Control, Knockdown, In Vivo